Overall, Eisai generated 601.2 billion yen (nearly $4 billion) over the last nine months of 2024, signaling 9% growth year-on-year. For the entire 12-month stretch ending March 31, the company ...

Europe to review safety data for Eisai-Biogen Alzheimer's drug January 31, 2025 U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma group to develop an ...

1 Day ESAIY 1.00% DJIA -1.69% S&P 500 -1.71% Health Care/Life Sciences -0.37% ...

Jean-François Richet, the screenwriter, filmmaker and producer behind some of France’s boldest thrillers such as “Mesrine” starring Vincent Cassel, has signed with CAA. Richet made a splash ...

Credit: Chinnapong/Shutterstock. The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen’s Leqembi (lecanemab-irmb) for maintenance ...

Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing regimen for Leqembi (lecanemab). Already approved ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Eisai reported strong Q3 2024 performance driven by its leading products, particularly LEQEMBI, which saw robust sales growth across key regions. Management expressed confidence in achieving its ...

“This is a match made in heaven,” said Rick Owens, who came to see how Ludovic de Saint Sernin would interpret the haute couture legacy of Jean Paul Gaultier. With the inimitable Michèle Lamy ...

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...